255 related articles for article (PubMed ID: 35076581)
1. Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Edinoff AN; Sanders NM; Lewis KB; Apgar TL; Cornett EM; Kaye AM; Kaye AD
Neurol Int; 2022 Jan; 14(1):75-88. PubMed ID: 35076581
[TBL] [Abstract][Full Text] [Related]
2. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Simon JA; Kingsberg SA; Portman D; Jordan R; Lucas J; Sadiq A; Krop J; Clayton AH
J Womens Health (Larchmt); 2022 Mar; 31(3):391-400. PubMed ID: 35230162
[No Abstract] [Full Text] [Related]
3. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.
Mayer D; Lynch SE
Ann Pharmacother; 2020 Jul; 54(7):684-690. PubMed ID: 31893927
[No Abstract] [Full Text] [Related]
4. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C
J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966
[TBL] [Abstract][Full Text] [Related]
5. Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.
Kingsberg SA; Simon JA
J Womens Health (Larchmt); 2020 Aug; 29(8):1101-1112. PubMed ID: 32460605
[TBL] [Abstract][Full Text] [Related]
6. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Kingsberg SA; Clayton AH; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Simon JA
Obstet Gynecol; 2019 Nov; 134(5):899-908. PubMed ID: 31599840
[TBL] [Abstract][Full Text] [Related]
7. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.
Pfaus JG; Sadiq A; Spana C; Clayton AH
CNS Spectr; 2022 Jun; 27(3):281-289. PubMed ID: 33455598
[TBL] [Abstract][Full Text] [Related]
8. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.
Koochaki P; Revicki D; Wilson H; Pokrzywinski R; Jordan R; Lucas J; Williams LA; Sadiq A; Krop J
J Womens Health (Larchmt); 2021 Apr; 30(4):587-595. PubMed ID: 33538638
[No Abstract] [Full Text] [Related]
9. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.
Croft HA
J Sex Med; 2017 Dec; 14(12):1575-1584. PubMed ID: 29198512
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.
Cipriani S; Alfaroli C; Maseroli E; Vignozzi L
Expert Opin Pharmacother; 2023 Jan; 24(1):15-21. PubMed ID: 36242769
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.
Barakeh D; Mdaihly H; Karaoui LR
Ann Pharmacother; 2024 May; ():10600280241253273. PubMed ID: 38767282
[TBL] [Abstract][Full Text] [Related]
12. Bremelanotide: First Approval.
Dhillon S; Keam SJ
Drugs; 2019 Sep; 79(14):1599-1606. PubMed ID: 31429064
[TBL] [Abstract][Full Text] [Related]
13. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.
Kingsberg SA; Clayton AH; Pfaus JG
CNS Drugs; 2015 Nov; 29(11):915-33. PubMed ID: 26519340
[TBL] [Abstract][Full Text] [Related]
14. Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder.
Simon JA
Postgrad Med; 2010 Nov; 122(6):128-36. PubMed ID: 21084789
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and Management of Hypoactive Sexual Desire Disorder.
Clayton AH; Kingsberg SA; Goldstein I
Sex Med; 2018 Jun; 6(2):59-74. PubMed ID: 29523488
[TBL] [Abstract][Full Text] [Related]
16. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.
Diamond LE; Earle DC; Heiman JR; Rosen RC; Perelman MA; Harning R
J Sex Med; 2006 Jul; 3(4):628-638. PubMed ID: 16839319
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Simon JA; Kingsberg SA; Portman D; Williams LA; Krop J; Jordan R; Lucas J; Clayton AH
Obstet Gynecol; 2019 Nov; 134(5):909-917. PubMed ID: 31599847
[TBL] [Abstract][Full Text] [Related]
18. Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment.
Parish SJ; Hahn SR
Sex Med Rev; 2016 Apr; 4(2):103-120. PubMed ID: 27872021
[TBL] [Abstract][Full Text] [Related]
19. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder.
Thurston L; Hunjan T; Mills EG; Wall MB; Ertl N; Phylactou M; Muzi B; Patel B; Alexander EC; Suladze S; Modi M; Eng PC; Bassett PA; Abbara A; Goldmeier D; Comninos AN; Dhillo WS
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 36189794
[TBL] [Abstract][Full Text] [Related]
20. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
Clayton AH; Althof SE; Kingsberg S; DeRogatis LR; Kroll R; Goldstein I; Kaminetsky J; Spana C; Lucas J; Jordan R; Portman DJ
Womens Health (Lond); 2016 Jun; 12(3):325-37. PubMed ID: 27181790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
